Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Editor
Ireland
+10 year(s) experience
Generics Bulletin
By David Wallace 18 Dec 2019
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
Generics Bulletin
By David Wallace 28 Nov 2019
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Generics Bulletin
By David Wallace 13 Nov 2019
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.
Topic Biosimilars
Generics Bulletin
By David Wallace 08 Nov 2019
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Topic Biosimilars Strategy
Generics Bulletin
By David Wallace 14 Aug 2019
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Topic Company analysis
Generics Bulletin
By David Wallace 30 Jul 2019
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
Topic Company analysis Biosimilars
Generics Bulletin
By David Wallace 07 Mar 2019
Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.
Topic BioPharmaceutical Biosimilars
Generics Bulletin
By David Wallace 07 Mar 2019
Several US senators have lent their backing to the draft Biologic Patent Transparency Act, as part of efforts to address “patent thickets” around brand biologics.
In Vivo
04 Dec 2019
Pink Sheet
26 Sep 2019
Pink Sheet
26 Jul 2019
In Vivo
03 Jul 2019
Scrip
16 May 2019
Pink Sheet
18 Apr 2019
In Vivo
20 Mar 2019
